Acute lymphoblastic leukemia (ALL) is a cancer of the white blood cells. Over the last few years, a number of agents have been launched that have improved treatment outcomes for patients with ALL, including monoclonal antibodies to CD19 (Amgen’s Blincyto) and CD22 (Pfizer’s Besponsa); and the first chimeric antigen receptor (CAR) T-cells for relapsed/refractory pediatric and young adult ALL patients, namely Novartis’ Kymriah. Nonetheless, chemotherapies are highly effective and remain the backbone of frontline ALL treatment. New targeted therapies in development, including novel kinase inhibitors, proteasome inhibitors, and immunomodulatory agents hold promise of providing ALL patients additional treatment options, but will need to be incorporated into the current algorithm.
Market covered: United States, France, Germany, Italy, Spain, and the United Kingdom.
Primary research: Six country-specific interviews with thought leaders (medical oncologist-hematologists).
Epidemiology: Diagnosed incident cases of ALL subpopulations; clinical and market-relevant drug-treatable populations.
Population segments in market forecast: First-line adult and pediatric ALL; relapsed/refractory adult and pediatric ALL.
Emerging therapies: Phase III: 3 drugs; Phase II: 2 drugs.
Product Description: Niche & Rare Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.